Giredestrant Shows Survival Benefits in Early Breast Cancer: Phase 3 lidERA BC Trial Results

Giredestrant improved survival for women with ER-positive, HER2-negative early breast cancer regardless of menopause status, according to results from the phase 3 lidERA BC clinical trial. The findings, presented at the ASCO Annual Meeting, indicate the drug’s efficacy as an adjuvant therapy compared to standard-of-care endocrine treatment, as reported by Shimoli Barot, MD.

The lidERA BC trial assessed the safety and efficacy of giredestrant, developed by Genentech and Roche, in a cohort of women with early-stage breast cancer. The study specifically focused on patients whose tumors were estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-).

Researchers compared the use of giredestrant against the current standard endocrine therapies.

How does menopause status affect breast cancer treatment?

The lidERA BC trial findings suggest giredestrant provides a survival benefit that transcends these hormonal categories.

Dr. Barot stated that the survival improvements were observed in both premenopausal and postmenopausal women.

What is the mechanism of giredestrant?

The adjuvant setting of the lidERA BC trial means the drug was administered after primary treatment to reduce the risk of the cancer returning.

How does this compare to other adjuvant therapies?

The introduction of giredestrant occurs alongside other targeted adjuvant options. Abemaciclib (Verzenio), produced by Eli Lilly & Co., is an approved adjuvant therapy.

The lidERA BC trial monitored the safety profile of giredestrant to determine if its survival benefits outweighed potential adverse effects compared to traditional care.

What happens next for giredestrant?

The presentation of these phase 3 results at the ASCO Annual Meeting marks a significant step. Genentech and Roche will likely use this data to seek authorization for giredestrant as an adjuvant option for ER-positive, HER2-negative early breast cancer.

Clinical adoption will depend on how the survival data compares to the long-term outcomes of current standard-of-care drugs.

Further analysis of the lidERA BC data may clarify which specific patient subgroups benefit most from giredestrant and whether it can be combined with other targeted therapies to further improve survival rates.